China’s National Development and Reform Commission (NDRC) is investigating the costs and prices of some domestic and foreign drugmakers, including units of GlaxoSmithKline Plc, Merck & Co., Novartis AG and Baxter International Inc. to improve the pricing system for medicines.

The NDRC, China’s top economic planning agency, will examine 27 companies for costs and 33 for pricing, according to a 2 July statement posted on the commission’s Evaluation Centre of Drug Pricing. Officials from the centre will visit the companies between July and October, according to the statement.

The investigation is being done so that drug prices can be adjusted in a more timely fashion, according to the statement. GlaxoSmithKline, Merck, Novartis, Baxter and Astellas Pharma Inc. are in the cost part of the review, it said. Bloomberg

Close